Bargou, Ralf C. 1961-
Ralf Bargou
VIAF ID: 3247148753688941320007 ( Personal )
Permalink: http://viaf.org/viaf/3247148753688941320007
Preferred Forms
- 100 1 _ ‡a Bargou, Ralf C. ‡d 1961-
- 100 0 _ ‡a Ralf Bargou
4xx's: Alternate Name Forms (7)
5xx's: Related Names (3)
- 510 2 _ ‡a Julius-Maximilians-Universität Würzburg ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 551 _ _ ‡a Sigmaringen ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _ ‡a Würzburg ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
Works
Title | Sources |
---|---|
Bedeutung von Apoptoseresistenzmechanismen für die Pathogenese und Therapie maligner Lymphome | |
Bedeutung von Osteoklasten für das Wachstum des Multiplen Myeloms | |
Deeskalation der Immuntherapie bei Patienten mit Multipler Sklerose | |
Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease — the “Breast cancer care for patients with metastatic disease” (BRE-4-MED) registry | |
Development of novel pharmacological drugs as inhibitores of HSF-1/HSP70-System for the treatment of multiple myeloma | |
Effects of LOX(L)-catalyzed extracellular matrix crosslinking on tumor growth, metabolism and malignity | |
Efficient Transient Transfection of Human Multiple Myeloma Cells by Electroporation - An Appraisal | |
Einfluss der Lysyloxidase-katalysierten Matrix-Quervernetzung auf Tumorwachstum, -metabolismus und -malignität | |
Einfluss des Multityrosinkinaseinhibitors Sunitinib auf die Proliferation und Steroidbiosynthese von Nebennierenkarzinomzellen in vitro | |
Entwicklung neuartiger pharmakologischer Wirkstoffe als Inhibitoren des HSF-1/HSP70-Systems zur Behandlung des Multiplen Myeloms | |
Entwicklung von Plasmiden mit multiplen short hairpin RNA-Expressionskassetten für den simultanen Knockdown onkogener Zielstrukturen im Multiplen Myelom | |
Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches | |
Establishment of a stable and inducible Multicassette-shRNA-Knockdown System in Myeloma Cell Lines and Adaption to the Evaluation of the NFκB-Pathway in Multiple Myeloms | |
Establishment of an isogenic cell line model for the investigation of the impact of mono- and biallelic TP53-inactivation on multiple myeloma | |
Etablierung eines isogenen Zelllinienmodells zur Untersuchung der Bedeutung mono- und biallelischer TP53-Inaktivierungen beim Multiplen Myelom | |
Etablierung eines stabilen induzierbaren Multikassetten-Systems für shRNA-Knockdown-Konstrukte in Myelom Zelllinien und Anwendung zur Analyse des NFκB-Signalwegs | |
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines | |
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease | |
Functional characterization of the Ras family small GTP binding protein RAL in multiple myeloma | |
Funktionelle Analyse onkogener Läsionen beim Multiplen Myelom mit potenzieller Bedeutung für einen refraktären Krankheitsverlauf | |
Funktionelle Charakterisierung von YB-1 im Zytoplasma des Multiplen Myeloms | |
Generating a vector system for the shRNA-mediated knockdown of Y-box binding protein 1 | |
Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation | |
Hitzeschock-Transkriptionsfaktor 1 (HSF1) als neues therapeutisches Ziel im Multiplen Myelom | |
IKK Inhibitor Bay 11-7082 Induces Cell Death Independent from Inhibition of Activation of NF kappa B Transcription Factors | |
Immunohistochemical analysis of the antibodies PAT-SM6 and PAT-LM1 of colon cancer and the metastases | |
impact of Osteoclasts on Multiple Myeloma growth | |
In vitro investigations into the therapeutic role of 2,6-dimethoxy-1,4-benzoquinones in Avemar, a medical nutriment with supportiv value | |
Isoform-spezifische Analyse der PI3-Kinase (Klasse I) im Multiplen Myelom | |
Long-term Follow-up of safety and efficacy of Blinatumomab in Non-Hodgkin-Lymphoma patients | |
Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines | |
MicroRNA-221 sensitizes prostate cancer cells to TRAIL via inhibition of SOCS-3 and PIK3R1 | |
miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro | |
Molekulare Analyse des IKK-Komplexes als Zielstruktur für potentielle Therapieoptionen im Multiplen Myelom | |
Pan-Raf-Inhibition as a new therapeutical strategy in Multiple Myeloma | |
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings | |
Patient-reported symptoms and distress as well as assessment of the therapeutic goal at first presentation to the radiation oncology department | |
Patientenberichtete Symptome und Belastungen sowie Einschätzung des Therapieziels bei Erstvorstellung in der Radioonkologie | |
PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma | |
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma | |
Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma | |
Retrospektive data evaluation of the tumor registry Würzburg from 2005-2013 analysing patients with non-small-cell lung cancer (NSCLC) with special regard to tyrosine kinase inhibitor (TKI) therapy in case of EGFR-mutation | |
Retrospektive Datenauswertung des Tumorregisters Würzburg im Zeitraum 2005 – 2013 bei Patienten mit Nicht-Kleinzelligem-Bronchialkarzinom (NSCLC) mit besonderer Betrachtung der Tyrosinkinaseinhibitor-Therapie bei EGFR-Mutation | |
Role and regulation of the heat shock proteins Hsp90 alpha and beta in Multiple Myeloma | |
Synaptophysin-Gen von Ratte und Mensch wird spezifisch in neuroendokrinen Zellen transkribiert | |
Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models | |
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 | |
Untersuchungen in vitro zur therapeutischen Wertigkeit von 2,6-Dimethoxy-1,4-benzochinonen im Supportivprodukt Avemar | |
Untersuchungen zur Expression und Funktion des „LIM and SH3 Domain Proteins“ (LASP-1) in Medulloblastomen | |
Validity of clinical, instrumental and imaging examination methods of temporomandibular joint diagnosis in patients with juvenile idiopathic arthritis | |
Wertigkeit klinischer, instrumenteller und bildgebender Untersuchungsverfahren der Kiefergelenksdiagnostik bei Patienten mit juveniler idiopathischer Arthritis |